<DOC>
	<DOCNO>NCT02212483</DOCNO>
	<brief_summary>Asthma one prevalent chronic respiratory disease , potential lifethreatening impact . Indeed , asthma still responsible thousand decease per year France , constitute public health problem country many country world . The economic burden asthma also high , term health care , indirect cost include lose work lose school day . A international French study show positive clinical impact Medical Indoor Environment Counselors ( MIECs ) visit home asthma patient , mainly pediatrics . It propose MIECs could contribute reduce patient exposure many allergen irritant , among , house dust mite allergen , formaldehyde mold . Most study show significant decrease hospitalization visit emergency ward asthma monocentric study eviction 1 identify risk factor . By contrast , meta-analysis underline additional study need evaluate effectiveness intervention adult , multicentric control manner , clinical , environmental economical endpoint .</brief_summary>
	<brief_title>Clinical Effectiveness Economical Impact Medical Indoor Environment Counselors Visiting Homes Asthma Patients</brief_title>
	<detailed_description>Methodology/Study schedule : A prospective multicenter randomise , open label , control trial blind evaluation primary evaluation criterion three parallel group patient . Procedures : Home intervention MIECs comprise diagnostic allergen/irritant exposure ( sample ) , advices allergen/irritant avoidance follow advice compliance . After randomisation agreement patient family , `` intervention group `` benefit first home intervention MIEC 4 week follow inclusion , final visit end study 12 month . Two comparative group identify : - `` control group `` benefit first home intervention MIEC without advice ( audit + sampling ) , final complete visit end study - `` non intervention `` group initial visit , benefit complete home intervention MIEC end study . Expected findings impact : If hypothesis home intervention MIECs cost-effective asthma control , relevant include service medical care management asthma patient reimbursement social security .</detailed_description>
	<mesh_term>Asthma</mesh_term>
	<criteria>age great equal 6 year less 45 ( &lt; 45 year ) , patient eligible control level asthma , sensitization one allergens demonstrate last 24 month prick test ( papule diameter &gt; 3 mm compare negative control &gt; 50 % positive control ) and/or specific IgE detection ( &gt; 0.35 U/mL ) , patient &gt; 15 year present reversibility ß2agonists &gt; 200 mL and/or &gt; 12 % compare initial FEV1 value ( test perform last 24 month ) patient ≥ 6 year ≤ 15 year present reversibility ß2agonists &gt; 200 mL and/or &gt; 12 % compare initial FEV1 value ( least life ) and/or positive metacholine challenge ( least life ) , patient sleep &gt; 6 night per week house individual affiliate 1 3 French social security ( match data French social security via SNIIRAM system ) , Only one patient per dwelling , Patient oral consent ( write attestation investigator ) chronic obstructive pulmonary disease ( COPD ) , identify occupational asthma , Move within 6 month home intervention predict first year inclusion , advice provide year inclusion home intervention MIEC smoker consumption 10 year 20 cigarettes/day , patient &lt; 18 year parent ( legal guardian ) oppose inclusion ECENVIR study , Major people object legal protection ( protection ( save ) justice , guardianship , supervision ( guardianship ) ) private person freedom</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>44 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Asthma</keyword>
	<keyword>Medical Indoor Environment Counselors</keyword>
	<keyword>Pediatric</keyword>
	<keyword>Environment</keyword>
	<keyword>Clinical effectiveness</keyword>
	<keyword>Economical impact</keyword>
</DOC>